This activity is supported by educational grants from Novartis Pharmaceuticals Corporation and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Psoriatic disease can have a substantial negative impact on patients’ quality of life. The treatments for psoriasis and psoriatic arthritis (PsA) can overlap, although additional measures should be taken in patients with PsA to slow progression of joint damage, manage pain, and promote mobility for optimal quality of life. This activity will provide learners with strategies for effective multidisciplinary management of psoriasis and PsA.
Dermatologists, dermatology NPs and PAs, and other clinicians who co-manage patients with psoriasis and PsA, including rheumatology and general practice/internal medicine clinicians
Upon completion of this activity, participants will be able to:
Describe the management of psoriasis, including setting treatment goals and selecting appropriate treatment based on disease and patient characteristics, safety and efficacy, and patient preference
Screen patients with psoriasis for PsA and the diagnostic criteria for PsA
Discuss strategies to overcome barriers to communication and collaboration with other healthcare professionals to develop a multidisciplinary team for the care of patients with psoriasis and PsA
Conflict Of Interest Disclosure Policy
Purdue University requires all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.
Alan Menter, MD Chief, Division of Dermatology Baylor University Medical Center Clinical Professor of Dermatology University of Texas Southwestern Medical School Dallas, TX
Dr. Menter has no conflicts of interest to disclose.
Eric M. Ruderman, MD Professor of Medicine Associate Chief, Clinical Affairs Division of Rheumatology Northwestern University Feinberg School of Medicine Chicago, IL
Dr. Ruderman has disclosed the following: Grants/Research Support: Corona Consultant: AbbVie, Amgen, Celgene, Lilly, Novartis, Janssen Biotech, Pfizer
Publishing Staff Disclosures
Kathleen Hines, Vice President, Editorial Services, MCM Education, has no conflicts of interest to disclose. Terry Ann Glauser, MD, MPH, Vice President, Medical Affairs, MCM Education, has no conflicts of interest to disclose.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Purdue University College of Pharmacy and MCM Education. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.
Purdue University designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditTM .
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
In this educational activity, the faculty reports that their presentation will not contain reference to investigational and/or off-label uses.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
To obtain credit, a score of 80% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.